Originally approved for an orphan disease, Glivec now has over 9 approvals and is a billion dollar product. Could another approval for diabetes further increase the commercial potential of this drug?
You can subscribe to the newsletter here. The Numedicus blog aims to discuss all things relevant to drug repurposing/therapeutic switching. Numedicus is found on the web at http://www.numedicus.co.uk. It is written by David Cavalla, whose picture and brief biographical details are found here.